Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation

Since its discovery, ADAM17, also known as TNFα converting enzyme or TACE, is now known to process over 80 different substrates. Many of these substrates are mediators of cancer and inflammation. The field of ADAM metalloproteinases is at a crossroad with many of the new potential therapeutic agents...

Full description

Bibliographic Details
Main Authors: Marcia L. Moss, Dmitry Minond
Format: Article
Language:English
Published: Hindawi Limited 2017-01-01
Series:Mediators of Inflammation
Online Access:http://dx.doi.org/10.1155/2017/9673537
id doaj-dfcab54e8f904d6a9e15533358ba6254
record_format Article
spelling doaj-dfcab54e8f904d6a9e15533358ba62542020-11-24T21:22:10ZengHindawi LimitedMediators of Inflammation0962-93511466-18612017-01-01201710.1155/2017/96735379673537Recent Advances in ADAM17 Research: A Promising Target for Cancer and InflammationMarcia L. Moss0Dmitry Minond1Verra Therapeutics, 127 Asbury Rd., Lansing, NY 14882, USARumbaugh-Goodwin Institute for Cancer Research, Nova Southeastern University, 3321 College Avenue, CCR 6th Floor, Fort Lauderdale, FL 33328, USASince its discovery, ADAM17, also known as TNFα converting enzyme or TACE, is now known to process over 80 different substrates. Many of these substrates are mediators of cancer and inflammation. The field of ADAM metalloproteinases is at a crossroad with many of the new potential therapeutic agents for ADAM17 advancing into the clinic. Researchers have now developed potential drugs for ADAM17 that are selective and do not have the side effects which were seen in earlier chemical entities that targeted this enzyme. ADAM17 inhibitors have broad therapeutic potential, with properties ranging from tumor immunosurveillance and overcoming drug and radiation resistance in cancer, as treatments for cardiac hypertrophy and inflammatory conditions such as inflammatory bowel disease and rheumatoid arthritis. This review focuses on substrates and inhibitors identified more recently for ADAM17 and their role in cancer and inflammation.http://dx.doi.org/10.1155/2017/9673537
collection DOAJ
language English
format Article
sources DOAJ
author Marcia L. Moss
Dmitry Minond
spellingShingle Marcia L. Moss
Dmitry Minond
Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation
Mediators of Inflammation
author_facet Marcia L. Moss
Dmitry Minond
author_sort Marcia L. Moss
title Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation
title_short Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation
title_full Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation
title_fullStr Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation
title_full_unstemmed Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation
title_sort recent advances in adam17 research: a promising target for cancer and inflammation
publisher Hindawi Limited
series Mediators of Inflammation
issn 0962-9351
1466-1861
publishDate 2017-01-01
description Since its discovery, ADAM17, also known as TNFα converting enzyme or TACE, is now known to process over 80 different substrates. Many of these substrates are mediators of cancer and inflammation. The field of ADAM metalloproteinases is at a crossroad with many of the new potential therapeutic agents for ADAM17 advancing into the clinic. Researchers have now developed potential drugs for ADAM17 that are selective and do not have the side effects which were seen in earlier chemical entities that targeted this enzyme. ADAM17 inhibitors have broad therapeutic potential, with properties ranging from tumor immunosurveillance and overcoming drug and radiation resistance in cancer, as treatments for cardiac hypertrophy and inflammatory conditions such as inflammatory bowel disease and rheumatoid arthritis. This review focuses on substrates and inhibitors identified more recently for ADAM17 and their role in cancer and inflammation.
url http://dx.doi.org/10.1155/2017/9673537
work_keys_str_mv AT marcialmoss recentadvancesinadam17researchapromisingtargetforcancerandinflammation
AT dmitryminond recentadvancesinadam17researchapromisingtargetforcancerandinflammation
_version_ 1725997155576971264